{"filings":[{"id":695361,"accession_number":"0001447028-26-000024","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-05-27T20:01:33+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Arbutus shareholders approve 2026 omnibus equity plan authorizing 16.3M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected all five director nominees: Androski, Beardsley, Bishop, Gline, Sawhney.","2026 Omnibus Share and Incentive Plan approved (138.9M for, 7.4M against); replaces 2011 and 2016 plans.","Plan authorizes 16,300,000 common shares for issuance as options, SARs, restricted shares, etc.","Non-binding advisory vote on executive compensation passed (137.6M for, 8.3M against).","Ernst & Young LLP ratified as independent auditor for FY 2026 (164.4M for, 2.1M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50163,"accession_number":"0001171843-26-003346","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-05-13T11:31:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.","Net income $169.7M vs net loss $24.5M in Q1 2025; diluted EPS $0.87.","Moderna settlement: $950M noncontingent payment due July 2026; Arbutus expects ~$178.7M.","Cash, equivalents and marketable securities $95.2M as of March 31, 2026.","FDA granted Fast Track designation for imdusiran for chronic hepatitis B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":179126000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92916,"accession_number":"0001171843-26-002458","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.","Imdusiran has achieved functional cure in 10 chronic HBV patients in clinical trials to date.","Fast Track may enable Accelerated Approval, Priority Review, or Rolling Review of a BLA or NDA.","CEO Lindsay Androski said designation validates imdusiran as an important drug candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104147,"accession_number":"0001171843-26-001838","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.","Net loss $33.5M for 2025 vs $69.9M in 2024; revenue $14.1M, up from $6.2M.","Moderna settlement: $950M noncontingent due July 2026; contingent $1.3B on 1498 ruling. Arbutus gets 20% of noncontingent after costs.","Two additional imdusiran Phase 2a patients achieved functional cure for chronic HBV, total 10 to date.","Company evaluating return of capital to shareholders in Q3 2026 after Moderna payment receipt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104146,"accession_number":"0001171843-26-001299","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Moderna to pay $950M upfront by July 8, 2026, plus $1.3B contingent on affirming rejection of Section 1498 defense.","Arbutus receives 20% of proceeds after litigation costs under its Genevant license; total potential $2.25B.","Arbutus evaluating a return of capital to shareholders in Q3 2026, tied to the upfront payment.","Settlement includes judgment of infringement and no invalidity on four patents; global license for SM-102 LNP mRNA vaccines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104145,"accession_number":"0001171843-26-000979","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus wins partial summary judgment in Moderna patent case; enablement goes to trial","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court bars Moderna's obviousness defense: IPR estoppel applies to '435 Patent, issue preclusion bars routine-optimization and phospholipid-range arguments.","Arbutus's motion to exclude Moderna's obviousness expert Dr. Anderson granted.","Moderna's enablement defense survives: Dr. Prud'homme's testimony creates genuine factual dispute; trial needed on whether claims require undue experimentation.","Moderna's derivation defense dismissed for lack of evidence.","Court upholds that prior IPR final written decisions trigger statutory estoppel even without appeal; Moderna cannot relitigate previously rejected arguments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104144,"accession_number":"0001171843-26-000676","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus patent case vs Moderna to proceed in Delaware; Section 1498 defense limited","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court denies Moderna's summary judgment on Section 1498 for most vaccine doses; only government employee doses go to Court of Federal Claims.","Prosecution history estoppel bars Arbutus from asserting doctrine of equivalents on molar ratio claims; literal infringement required.","Indefiniteness challenges dismissed; factual disputes on patent validity reserved for jury.","Case covers 500M+ doses of Moderna's COVID-19 vaccine; $8.2B in government spending referenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104143,"accession_number":"0001171843-26-000303","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"EPO revokes Arbutus' European patent EP 2279254; company plans appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["EPO Board of Appeal revoked Arbutus' European patent EP 2279254 on Jan 15, 2026; verbal decision without reasons; written decision expected in months.","Opposition originally filed by Moderna affiliates and Merck in April 2018; two prior EPO decisions had upheld amended patent.","Company plans to petition EPO Enlarged Board of Appeal upon receipt of written decision; decision affects cases vs Moderna in Switzerland and UPC Case UPC_CFI_191/2025.","Decision does not impact litigations in US, Japan, Canada, other UPC case (UPC_CFI_192/2025), or cases against Pfizer/BioNTech.","Company notes added-matter standard used by EPO does not apply in US or other jurisdictions; no impact on other patent cases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120415,"accession_number":"0001171843-25-007879","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus updates LNP litigation; Moderna trial March 2026, Pfizer/BioNTech awaits scheduling","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Global COVID-19 vaccine sales since launch total ~$145BN between Moderna and Pfizer/BioNTech.","US Moderna jury trial set for March 9, 2026 in Delaware; summary judgment/Daubert rulings expected before trial.","Ex-US Moderna litigation initial hearings expected in 2026 in UPC, Japan, Switzerland, Canada.","Pfizer/BioNTech litigation: Markman ruling in Sep 2025 viewed favorably; awaiting trial scheduling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120414,"accession_number":"0001171843-25-007256","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.","Revenue fell to $0.5M from $1.3M due to lower Alnylam ONPATTRO royalties.","Cash, equivalents and marketable securities $93.7M at Sep 30, 2025, down from $122.6M at Dec 31, 2024.","Moderna US trial set for March 2026; Pfizer-BioNTech claim construction ruling favorable in Sep 2025.","Imdusiran: 46% of Phase 2a patients discontinued all treatment; 94% of long-term follow-up off treatment up to 2+ years."],"consensus_eps_estimate":-0.0316,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":13032000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120413,"accession_number":"0001171843-25-006316","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus announces four abstracts accepted for AASLD, including AB-101 Poster of Distinction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three abstracts on imdusiran and one on AB-101 accepted for AASLD Liver Meeting Nov 7-11, 2025 in Washington DC.","Imdusiran integrated safety analysis shows well-tolerated at 60-90 mg Q8W for up to 48 weeks dosing and follow-up.","Imdusiran may enhance pegylated interferon responsiveness in HBV genotype B/C patients vs historical data.","AB-101 up to 30 mg QD for 28 days was well tolerated; 83% mean PD-L1 receptor occupancy at 30 mg dose.","AB-101 abstract selected as Poster of Distinction; data on safety, PK, PD and HBV biomarkers will be presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136994,"accession_number":"0001171843-25-005815","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus wins claim construction ruling in patent suit vs Pfizer/BioNTech over COVID-19 vaccine LNP technology","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court adopted Arbutus's proposed construction for 'fully encapsulated' as 'contained inside' in five LNP patents.","Court rejected Pfizer/BioNTech's proposal and declined to add 'as distinct from partially' used in prior Moderna ruling.","Patent claims cover lipid nanoparticle compositions used in COMIRNATY COVID-19 vaccine; damages sought.","Ruling narrows scope of disputed terms, strengthening Arbutus's infringement case; trial on merits pending.","Arbutus and licensee Genevant Sciences assert five patents against Pfizer/BioNTech in New Jersey action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136993,"accession_number":"0001171843-25-005076","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Arbutus Q2 net income $2.5M; revenue $10.7M; Dr. Sawhney joins Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 net income of $2.5M ($0.01 per share) vs loss of $19.8M in Q2 2024; total revenue $10.7M, up from $1.7M.","Revenue increase primarily due to recognition of deferred revenue from termination of Qilu partnership; cash and equivalents $98.1M.","Dr. Roger Sawhney appointed to Board effective Aug 4, 2025, succeeding Anuj Hasija who resigned to join Vertex.","In Moderna U.S. litigation, summary judgment phase began July 2025; jury trial scheduled March 2026.","R&D expenses down to $5.5M from $15.6M due to restructuring; G&A down to $3.3M from $7.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154273,"accession_number":"0001171843-25-004094","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Arbutus reacquires Greater China rights to imdusiran from Qilu Pharma; launches HBV SAB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutual termination of License Agreement with Qilu Pharmaceutical for imdusiran in Greater China; no payments and all rights revert to Arbutus.","Arbutus now holds global rights to imdusiran; reports 8 patients achieved functional cure in Phase 2a trials IM-PROVE I/II to date.","New Scientific Advisory Board formed with five HBV experts to advise on late-stage clinical development of cHBV pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154272,"accession_number":"0001447028-25-000104","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arbutus shareholders elect all five director nominees, approve say-on-pay and auditor at 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Androski, Beardsley, Bishop, Gline, Hasija (avg 123M votes for).","Non-binding advisory vote on named executive officer compensation passed (122.8M for, 7.0M against).","Appointment of Ernst & Young as independent auditor for FY2025 ratified (157.7M for).","Broker non-votes (28.2M) were present on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154271,"accession_number":"0001171843-25-003153","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.","Cash, equivalents & securities $112.7M as of Mar 31, down from $122.6M at Dec 31, 2024.","Imdusiran combo therapy functionally cured 8 cHBV patients to date; 2 received no interferon.","AB-101 oral PD-L1 inhibitor achieved 100% receptor occupancy in 11 of 13 healthy subjects at 40mg.","Moderna U.S. jury trial set for Sep 29, 2025; claim construction for Pfizer/BioNTech expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1764000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154270,"accession_number":"0001171843-25-002841","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus presents HBV functional cure data from imdusiran combo; AB-101 safety at EASL 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In Phase 2a IM-PROVE II, imdusiran + VTP-300 + low-dose nivolumab led to 15.3% functional cure rate (2/13) in patients with baseline HBsAg <1000 IU/mL.","3 patients in nivolumab cohort achieved HBsAg loss and seroconversion at week 48.","AB-101 Phase 1a/1b Part 3: 10mg once daily for 28 days well tolerated with PD-L1 receptor occupancy similar to healthy volunteers; no liver dysfunction.","Across all imdusiran Phase 2a trials, 8 patients functionally cured, 7 with baseline HBsAg <1000 IU/mL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154269,"accession_number":"0001171843-25-002401","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus announces five abstracts on imdusiran and AB-101 accepted at EASL 2025, including late-breaker","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five abstracts accepted for poster presentation at EASL Congress 2025 (May 7-10, Amsterdam); one late-breaker (LB25153).","Abstract 1768: IM-PROVE I study shows HBsAg at baseline and NA discontinuation associated with functional cure in CHB subjects.","Abstract 2043: Rapid HBV RNA decline during imdusiran lead-in, then transient increases with interferon, linked to HBsAg seroclearance.","AB-101 (oral PD-L1 inhibitor) data: well-tolerated in healthy/subjects, dose-responsive PD-L1 RO, high liver biodistribution.","Late-breaker LB25153: off-treatment antiviral efficacy and safety of repeat imdusiran + VTP-300 with/without nivolumab in CHB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154268,"accession_number":"0001447028-25-000093","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Arbutus Biopharma finalizes separation agreements with ex-CMO and ex-CFO; updates Moderna trial date","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Karen Sims terminated without cause effective March 25, 2025; enters 30-day consulting agreement with hourly fee and extended option exercise to March 24, 2026.","CFO David Hastings terminated without cause effective March 27, 2025; separation agreement extends option exercise to March 26, 2026.","Patent litigation vs Moderna: District of Delaware moved trial start from September 24 to September 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172858,"accession_number":"0001171843-25-001760","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arbutus reports FY2024 net loss $69.9M; cuts workforce 57%, appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2024 was $69.9M ($0.38/share) vs $72.8M ($0.44) in 2023; revenue $6.2M down from $18.1M.","Cash and marketable securities $122.6M at Dec 31, 2024; ATM program terminated.","Workforce reduced by 57% in Q1 2025, retaining 19 employees; expects $11-13M restructuring charge.","Tuan Nguyen appointed CFO effective March 28, 2025, replacing David Hastings; General Counsel and CMO departures.","Moderna U.S. LNP patent trial scheduled for Sept 2025; Pfizer/BioNTech claim construction ruling pending; international lawsuits filed March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172857,"accession_number":"0001171843-25-001188","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Arbutus and Genevant file 5 international patent lawsuits against Moderna; terminate sublicense for breach","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Agreement entitles Arbutus to damages specifically allocated to Moderna's mRESVIA in pending U.S. litigation; if no allocation, parties discuss in good faith.","Arbutus terminated 2016 sublicense with ModernaTX for material breach over unpaid milestone/royalty payments; 60-day cure period.","Five lawsuits filed in Canada, Japan, Switzerland, and two UPC actions covering 30 countries, seeking injunctions and monetary relief against Spikevax and mRESVIA.","U.S. jury trial against Moderna in Delaware currently scheduled for September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172856,"accession_number":"0001171843-25-001049","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.","Lindsay Androski named President and CEO, replacing interim CEO McElhaugh; she also serves as board chair.","Androski receives $515k salary, 45% target bonus, and ~$750k option grant; three new directors are from Roivant.","Company will pause investor meetings to review strategic options for hepatitis B pipeline and development plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172855,"accession_number":"0001171843-25-000193","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.","Plans placebo-controlled Phase 2b trial of imdusiran + interferon + NA in HBeAg-negative cHBV with HBsAg ≤1000 IU/mL in H1 2025; target N=170.","IM-PROVE I Phase 2a showed 50% functional cure (3/6) in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; 25% overall.","AB-101 oral PD-L1 Phase 1a/1b Part 3 (28-day repeat doses) data expected in H1 2025; next steps determined after.","LNP litigation: claim construction hearing for Pfizer/BioNTech on Dec 18, 2024; Moderna trial set for Sept 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189866,"accession_number":"0001171843-24-006400","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus reports 50% functional cure in HBsAg<1000 IU/mL patients with imdusiran + IFN in Phase 2a","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort A1: 50% (3/6) functional cure in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; overall 25% (3/12).","IM-PROVE II Group C: 23% (3/13) achieved HBsAg loss at Week 48 with imdusiran, VTP-300 and low-dose nivolumab.","Both regimens generally well-tolerated; no imdusiran/IFN-related SAEs or discontinuations in IM-PROVE I.","Data to be presented at AASLD The Liver Meeting 2024 on November 18. Corporate presentation updated on website.","Combination of imdusiran and interferon shows potential for finite curative treatment in chronic HBV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189865,"accession_number":"0001171843-24-006039","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.","Cash and investments $130.8M; 2024 cash burn expected $63M-$67M; runway into Q4 2026.","Imdusiran HBsAg loss data from IM-PROVE I/II to be presented at AASLD Nov 2024; additional follow-up and nivolumab cohort data.","AB-101 oral PD-L1 inhibitor advanced to Part 3 in cHBV patients; preliminary data expected H1 2025.","LNP litigation vs Moderna trial set Sept 2025; Pfizer claim construction Dec 18, 2024; restructuring charge $3.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":4597000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189864,"accession_number":"0001171843-24-005618","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus to present imdusiran Phase 2a data in 4 posters at AASLD, including 2 late-breakers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four poster presentations at AASLD 2024 (Nov 15-19, San Diego) feature imdusiran, an RNAi therapeutic for chronic HBV.","Late-breaking posters will show IM-PROVE I and IM-PROVE II Phase 2a trial data.","Immune biomarker profiling in subjects treated with imdusiran + pegylated interferon reveals phases of immune activation linked to HBsAg seroconversion.","Imdusiran target site is highly conserved across HBV genotypes A-E; SNPs do not affect HBsAg decline.","Posters will be available on Arbutus website from November 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189863,"accession_number":"0001447028-24-000084","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CSO Michael J. Sofia to retire Dec 31, 2024; amendment clarifies severance and non-compete","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO Michael J. Sofia will retire effective December 31, 2024; amendment to employment agreement dated Oct 11, 2024.","Sofia eligible for 2024 annual target cash bonus ($204,800) prorated by corporate score, payable ~Feb 15, 2025.","Amendment carves out coronavirus and HDV-only treatments from non-compete; also allows academic teaching/research.","Sofia must sign release to receive benefits; 21-day consideration period and 7-day revocation.","No named replacement; retirement is planned, not abrupt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206380,"accession_number":"0001447028-24-000066","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Arbutus and Moderna agree to extend patent trial schedule to Sept 2025","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbutus, Genevant filed stipulation with Moderna extending case schedule in COVID-19 vaccine patent suit.","Parties request trial start moved to September 24, 2025, subject to court approval.","Lawsuit seeks damages for patent infringement in manufacture and sale of MRNA-1273.","Stipulation cites need to accommodate outstanding discovery from Moderna and third parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206379,"accession_number":"0001171843-24-004324","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.","Workforce reduction of 40% (discontinuing HBV discovery); one-time restructuring charge $3-4M in Q3.","Cash, cash equivalents & investments $148.5M; cash runway extended into Q4 2026 (2024 cash burn guidance $63-67M).","IM-PROVE I data: 33% of patients achieved undetectable HBsAg; 67% for those with baseline HBsAg <1000 IU/mL.","LNP litigation vs Moderna trial set for April 21, 2025; Pfizer/BioNTech ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":3258000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223493,"accession_number":"0001171843-24-003323","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.","80% treatment arm vs 16% placebo had HBsAg <100 IU/mL; 60% vs 0% <10 IU/mL at 24 weeks post-EOT.","84% of treatment arm patients met NA therapy discontinuation criteria vs 53% in placebo arm.","Treatment generally safe; no SAEs or Grade 3/4 AEs; injection-site reactions and transient ALT increases.","Additional cohort evaluating nivolumab combination fully enrolled; preliminary data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223492,"accession_number":"0001171843-24-003302","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus Phase 2a: imdusiran+IFN yields sustained undetectable HBsAg in 33% at 24 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["33.3% (4/12) on 48wk imdusiran + 24wk IFN had undetectable HBsAg at EOT, sustained 24wk post-treatment.","All six patients with sustained HBsAg loss seroconverted with high anti-HBsAg antibodies (43.8 to >1,000 mIU/mL).","Two of six patients stopped all therapy and maintain undetectable HBsAg and HBV DNA at 12 weeks off therapy.","No SAEs related to imdusiran or IFN; most common TEAEs were transient ALT elevations and injection site bruising."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223491,"accession_number":"0001447028-24-000061","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Arbutus shareholders approve 9.5M share increase under 2016 Omnibus Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment increases aggregate authorized shares by 9,500,000 common shares.","All seven director nominees (Torti, McElhaugh, Burgess, Henriques, Manchester, Meyers, Rewolinski) elected.","Non-binding advisory vote on named executive officer compensation approved (99.3M for, 13.5M against).","Ernst & Young LLP appointed as independent auditor for FY 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223490,"accession_number":"0001171843-24-003042","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).","28% of subjects on imdusiran + 24 weeks of IFN achieved HBsAg below lower limit of quantification with anti-HBs.","Imdusiran followed by VTP-300 maintained lower HBsAg levels; more subjects qualified to stop NA therapy and remain off therapy.","Additional on-treatment, follow-up, and NA discontinuation data to be presented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223489,"accession_number":"0001171843-24-002453","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.","Cash, equivalents & marketable securities $137.9M; expects cash runway through Q2 2026.","End-of-treatment data for two Phase 2a imdusiran trials to be presented at EASL June 2024.","AB-101 oral PD-L1 inhibitor Part 1 showed dose-dependent receptor occupancy; moving to multiple-ascending dose part.","Favorable claim construction ruling in Moderna LNP lawsuit; trial set for April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1532000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223488,"accession_number":"0001171843-24-002452","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Arbutus CSO Michael Sofia to retire Dec 31, 2024; no successor named yet.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Sofia, co-founder and Chief Scientific Officer, notified retirement effective December 31, 2024.","Sofia is a Lasker award-winning antiviral drug discovery scientist with 38-year career.","Interim CEO Michael McElhaugh thanked Sofia for contributions to HBV functional cure development.","No replacement for CSO role announced; company continues clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223487,"accession_number":"0001171843-24-001830","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus Biopharma Announces Claim Construction Ruling in Patent Lawsuit Against Moderna","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court agreed with Arbutus and Genevant that the claimed mol. % ranges for total lipid ('069 patent) are not limited to 'finished' particles and include standard variation.","Court held no limitation on mol. % of the claimed cationic lipid with protonatable tertiary amine ('378 patent) as argued by plaintiffs.","Court construed 'fully encapsulated' mRNA ('651 patent) to mean mRNA wholly contained inside lipid vesicles, distinct from partial encapsulation.","Arbutus and Genevant seek fair compensation for Moderna's use of LNP technology in its COVID-19 vaccine MRNA-1273 without which the vaccine would not have succeeded.","Michael J. McElhaugh, Interim CEO, stated the company is pleased with the ruling and remains committed to protecting its intellectual property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242940,"accession_number":"0001171843-24-001068","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.","Cash, cash equivalents and investments $132.3M at Dec 31, 2023; 2024 net cash burn guided $63-67M.","Moderna LNP litigation claim construction held Feb 8, 2024; trial set for April 21, 2025.","Phase 2a imdusiran combo data readouts expected H1 2024; third imdusiran Phase 2a trial to start H1 2024.","AB-101 Phase 1a/1b preliminary data (healthy subjects) expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":18141000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242939,"accession_number":"0001171843-24-000113","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus provides 2024 outlook: $132M cash, reduced burn, multiple Phase 2a readouts expected in 1H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and investments ~$132M at Dec 31, 2023; net burn expected $63-67M in 2024 vs ~$85M in 2023.","Cash runway extends into Q1 2026.","End-of-treatment data from imdusiran Phase 2a trials AB-729-201 and AB-729-202 expected 1H 2024.","Third Phase 2a imdusiran trial (AB-729-203, with durvalumab) to begin in 1H 2024; AB-101 Phase 1a/1b data also expected 1H 2024.","Moderna LNP claim construction hearing set Feb 8, 2024; trial expected 1H 2025. Pfizer/BioNTech lawsuit ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242938,"accession_number":"0001447028-24-000006","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Collier retires, gets $207K bonus; interim CEO McElhaugh gets $515K salary + $127.5K stipend","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Collier retired as CEO effective Dec 31, 2023; receives prorated 50% target bonus of $207,058.","Collier enters consulting agreement for 3 months at $400/hour; RSUs and stock options continue to vest during term.","Michael McElhaugh appointed Interim President & CEO; base salary increased to $515,000, target bonus 45%, additional yearly stipend of $127,500.","McElhaugh will be nominated for election to the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260307,"accession_number":"0001171843-23-006951","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus and Barinthus report preliminary Phase 2a data: imdusiran + VTP-300 sustains low HBsAg levels in cHBV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.","Mean HBsAg reduction of -1.86 log10 after 24 weeks of imdusiran; all VTP-300 patients maintained <100 IU/mL through week 48.","60% of VTP-300 patients had HBsAg <10 IU/mL through week 48; all qualified to stop NA therapy.","HBV-specific T cell IFN-γ production enhanced vs placebo; no serious AEs, Grade 3/4 AEs, or discontinuations.","Updated corporate presentation posted on company website with additional pipeline details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260306,"accession_number":"0001171843-23-006796","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus cuts workforce 24%, extends cash runway to Q1 2026; CEO to retire","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by 24% affecting research; one-time charge ~$1.1M in Q4 2023.","Cash, cash equivalents & investments $144.7M as of Sep 30; cash runway extended into Q1 2026.","Net loss $20.1M ($0.12 per share) for Q3 2023 vs. $17.6M loss in Q3 2022.","CEO William Collier to retire at end of 2023; COO Michael McElhaugh to serve as interim CEO.","Preliminary Phase 2a data for imdusiran + VTP-300 at AASLD; AB-101 Phase 1a/1b dosing continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260305,"accession_number":"0001171843-23-006795","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arbutus Biopharma CEO William Collier to retire Dec 31; COO McElhaugh named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William H. Collier retires as President, CEO, and director effective Dec 31, 2023.","Michael J. McElhaugh, Co-founder and COO, appointed interim President and CEO effective Jan 1, 2024.","McElhaugh will also join the Board on Jan 1, 2024.","Collier's retirement is not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260304,"accession_number":"0001171843-23-006206","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus announces multiple abstracts accepted for AASLD 2023, including late-breaking imdusiran data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Late-breaking poster on imdusiran (AB-729) followed by VTP-300 or placebo in chronic hepatitis B subjects.","Poster #1459-C shows baseline HBV SNPs do not impact HBsAg reductions from imdusiran.","Oral presentation on 48-week vebicorvir + imdusiran + NrtI combination in eAg-negative CHB (Nov 12).","Preclinical data on oral small-molecule liver-tropic PD-L1 inhibitor for HCC (Nov 13)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277600,"accession_number":"0001171843-23-005658","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus discontinues AB-161 and coronavirus programs, focuses on HBV; cash runway extended to Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.","Discontinuing coronavirus combination therapy (AB-343) due to unfavorable PK profile in IND-enabling studies.","Dosed first subject in Phase 1a/1b for oral PD-L1 inhibitor AB-101; preliminary data expected H1 2024.","Pipeline changes expected to extend cash runway through Q3 2025.","Ongoing LNP patent litigations against Moderna (claim construction hearing Feb 2024) and Pfizer/BioNTech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277599,"accession_number":"0001171843-23-004945","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).","Cash $163.5M; runway into Q1 2025; net cash burn guidance $90-95M for 2023.","AB-729 (imdusiran) Phase 2a data at EASL: mean HBsAg decline ~1.6 log10; four patients reached below LLOQ.","AB-101 (oral PD-L1) received NZ Medsafe approval for Phase 1 after FDA clinical hold; dosing starts Q3 2023.","Melissa Rewolinski appointed to board; Karen Sims promoted to CMO; Christopher Naftzger named GC and CCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":11338000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277598,"accession_number":"0001171843-23-004458","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arbutus appoints Melissa V. Rewolinski, PhD to its board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melissa V. Rewolinski appointed to board effective July 12, 2023; board expands to seven members.","She joins Compensation Committee; receives $40,000 annual retainer plus $7,500 for committee service.","Granted option for 110,000 common shares vesting over 3 years; exercise price based on July 12 closing price.","Dr. Rewolinski brings 20+ years pharma experience; previously at Intercept, Amira, Pfizer; currently MVR Consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277597,"accession_number":"0001171843-23-004433","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus appoints Karen Sims as CMO, Christopher Naftzger as GC and CCO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Karen Sims promoted from VP Clinical Development to Chief Medical Officer, effective immediately.","Christopher Naftzger appointed General Counsel and Chief Compliance Officer; Dr. Elizabeth Howard remains advisor on patent litigation.","Naftzger granted inducement option for 500,000 common shares at July 10, 2023 closing price, vesting over 4 years.","Sims has 12+ years experience, previously at Bristol-Myers Squibb; Naftzger has 25+ years legal experience, most recently at Nabriva Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295583,"accession_number":"0001171843-23-004029","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus doses first patient in Phase 2a triple combo arm adding nivolumab for chronic HBV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in additional arm of AB-729 Phase 2a trial including nivolumab (Opdivo) with VTP-300.","Arm evaluates low-dose nivolumab plus VTP-300 boosters after AB-729 and NA therapy to reduce HBsAg in chronic HBV.","Preliminary data from this arm expected in 2024; original arm data expected H2 2023.","Enrollment complete in original arm; approximately 20 patients to be enrolled in new open-label arm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295582,"accession_number":"0001171843-23-004026","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus reports preliminary AB-729 + IFN data at EASL; HBsAg declines seen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean HBsAg decline of 1.6 log10 at week 24 during AB-729 lead-in phase.","93% of patients (38/41) achieved HBsAg <100 IU/mL during treatment period.","Four patients reached HBsAg below LLOQ during IFN treatment; no sustained seroclearance yet.","No serious adverse events, discontinuations, or AB-729-related discontinuations reported.","Trial ongoing; three patients evaluated to stop NA therapy, one met criteria to stop."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295581,"accession_number":"0001171843-23-003807","cik":1447028,"company_name":"Arbutus Biopharma Corp","ticker":"ABUS","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arbutus to present AB-729 and AB-836 data at EASL Congress 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AB-729 + IFN in virally suppressed chronic HBV: well tolerated, mean HBsAg decline >1.6 log10 after 24 weeks.","88% of subjects achieved HBsAg <100 IU/mL; 2 subjects reached HBsAg <LLOQ during IFN treatment.","AB-836 capsid inhibitor: no viral breakthrough or enrichment of resistant variants after 28 days across 48 subjects.","Multiple core protein variants observed at higher frequencies, suggesting viral plasticity at those sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":890895021.1681035,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-07T23:59:59+00:00|295581"}